Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.5K
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.7K
Rh Blood Group01:19

Rh Blood Group

2.6K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.6K
X-linked Traits01:19

X-linked Traits

58.1K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
58.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subchondral Bone Injections for the Treatment of Knee Osteoarthritis.

The archives of bone and joint surgery·2026
Same author

Clinical, Functional and Radiological Results of Bicondylar Tibial Plateau Fractures (AO41.C) Treated by Osteosynthesis with Plates and Screws.

The archives of bone and joint surgery·2026
Same author

Circumstances that Increase the Risk of Periprosthetic Joint Infection after Total Knee Arthroplasty.

The archives of bone and joint surgery·2026
Same author

Is Pharmacologic Prophylaxis for Venous Thromboembolism Necessary in People With Hemophilia After Total Knee and Hip Arthroplasty?

The archives of bone and joint surgery·2026
Same author

Conventional Titanium Acetabular Cups vs. Trabecular Titanium Acetabular Cups in Primary Total Hip Arthroplasty: Ten-year Follow-up Clinical and Radiological Results.

The archives of bone and joint surgery·2026
Same author

Psychosocial Outcomes and Quality of Life in Patients with Hemophilia a Without Inhibitors: The HemoLIFE Study.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Dec 27, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.1K

'Do not Do' Recommendations in Hemophilia.

Hortensia De la Corte-Rodriguez1, E Carlos Rodriguez-Merchan2, M Teresa Alvarez-Roman3

  • 1Department of Physical Medicine and Rehabilitation, La Paz University Hospital-IdiPaz, Madrid, Spain.

Cardiovascular & Hematological Disorders Drug Targets
|March 6, 2020
PubMed
Summary
This summary is machine-generated.

This study outlines 13 essential "do not do" recommendations for hemophilia care. Adhering to these guidelines improves patient safety and optimizes healthcare resource utilization in managing this bleeding disorder.

Keywords:
Hemophiliaclinical guidelinesdo not dohealth resourcespatient safetyrecommendations

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.0K
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.3K

Related Experiment Videos

Last Updated: Dec 27, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.1K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.0K
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.3K

Area of Science:

  • Hematology
  • Patient Safety
  • Clinical Practice Guidelines

Background:

  • Healthcare practices should be evaluated for value and efficacy.
  • Initiatives are crucial for enhancing patient safety and optimizing health resource use.
  • Establishing clear guidelines is essential for effective hemophilia management.

Purpose of the Study:

  • To compile a comprehensive list of "do not do" recommendations specifically for hemophilia care.
  • To provide evidence-based guidance to clinicians for improving patient outcomes.
  • To establish a foundational resource for hemophilia management.

Main Methods:

  • A thorough review of existing literature was conducted.
  • Current clinical guidelines for hemophilia management were analyzed.
  • The best available evidence was synthesized to formulate recommendations.

Main Results:

  • Thirteen key "do not do" recommendations were identified.
  • These include avoiding delayed factor administration, specific medication uses (e.g., desmopressin, NSAIDs), and certain procedures (e.g., intramuscular injections, routine radiographs).
  • Recommendations also cover managing inhibitors, physical activity, and surgical interventions.

Conclusions:

  • The compiled recommendations offer valuable guidance for hemophilia management across various care settings.
  • This initiative represents a novel contribution to the field of hemophilia care.
  • Implementing these "do not do" recommendations can significantly improve patient safety and care quality.